Adjuvant Imatinib Prolongs RFS and OS in Patients with Resected GIST Harbouring KIT Exon 9 Mutations By Ogkologos - March 10, 2026 303 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an international retrospective cohort study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR New treatment for Waldenstrom’s macroglobulinaemia in England October 1, 2022 177Lu-DOTATATE Shows Promising Efficacy in the Treatment of Patients with Progressive... September 2, 2025 FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma January 25, 2021 Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for... August 27, 2025 Load more HOT NEWS Baby Boy Can’t Stop Smiling After Surgery Allows Him To See... Cancer Prevention and Screening Account for Most Cancer Deaths Averted Among... EMA Recommends Extension of Indications for Datopotamab Deruxtecan Women Over Age 65 Years with Pathogenic Variants in Cancer Predisposition...
